サンプル依頼リスト カート
  • English
  • Korean
表紙：骨壊死治療の世界市場-2023年～2030年
市場調査レポート
商品コード
1374802

骨壊死治療の世界市場-2023年～2030年

Global Osteonecrosis Treatment Market -2023-2030

出版日
ページ情報
英文 186 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.57円
骨壊死治療の世界市場-2023年～2030年
出版日: 2023年11月01日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

概要

骨壊死（osteonecrosis）は、血管壊死（avascular necrosis）または無菌性壊死（aseptic necrosis）とも呼ばれ、血流不足により骨組織が死滅または壊死する病状です。特定の骨への血流が妨げられたり制限されたりすると、骨細胞は劣化し、最終的には屈服します。

世界の骨壊死治療薬市場には、非ステロイド性抗炎症薬（NSAIDs）、コレステロール低下薬、血液希釈薬など様々な治療薬が含まれます。市場は、骨壊死の有病率の増加、ステロイドの過剰使用、外傷、老人人口の増加、技術の進歩などの要因によって牽引されています。

市場促進要因：市場抑制要因

アルコール消費量の増加

アルコール消費量の増加は、骨壊死治療市場の主要促進要因の一つです。アルコールの過剰摂取は、血液循環を阻害し、骨、特に股関節や膝関節のような体重のかかる関節への血流を減少させるため、骨壊死の重要な危険因子です。

例えば、米国国立医学図書館の2023年の論文によると、アルコール摂取は骨壊死の主要な危険因子であり、骨壊死を患う人の20～45％が影響を受けています。さらに、常習的飲酒者における無菌性壊死の有病率は5.3％と高いことが報告されています。

さらに、鎌状赤血球貧血の有病率が上昇しています。鎌状赤血球貧血は、奇形の鎌状の赤血球が小さな血球を塞ぎ、骨を含む臓器への血液供給を制限することを特徴とする遺伝的血液疾患であり、骨壊死を引き起こす可能性があります。この血液供給の低下は虚血を引き起こし、酸素と栄養素の不足により骨組織細胞を死滅させる。例えば、国立医学図書館の2022年の論文によると、大腿骨頭の骨壊死は鎌状赤血球症の患者で22％、最大50％と報告されています。

さらに、ステロイドの使用数の増加、全身性エリテマトーデスの有病率の増加、ゴーシェ病、腎臓移植などの他の要因も、予測期間中の市場を牽引すると予想されます。

市場力学：市場抑制要因

利用可能な治療法に伴う高コスト、治療薬に関連するリスク要因。さらに、病気の症状に対する認知度が低く、進行した病期に対する治療選択肢が乏しいため、しばしば人工関節置換術が必要となります。そのため、予測可能な期間中、骨壊死治療市場は抑制されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • アルコール消費量の増加
    • 抑制要因
      • 治療に伴う高コスト
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ戦争の影響分析
  • DMI意見

第6章 COVID-19分析

第7章 タイプ別

  • 外傷性
  • 非外傷性

第8章 治療タイプ別

  • 薬物療法
    • 抗骨吸収薬
    • 非ステロイド性抗炎症薬
    • コレステロール低下薬
    • 血液サラサラ薬
    • その他
  • 外科手術
    • 体幹減圧手術
    • 骨切り術
    • 骨移植
    • 人工関節置換術
    • その他

第9章 販売チャネル別

  • エンドユーザー
    • 病院
    • 整形外科クリニック
    • 外来手術センター
    • 専門クリニック
    • その他
  • 流通チャネル
    • 病院薬局
    • 小売薬局
    • オンライン薬局

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Novartis AG
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Pfizer Inc
  • Teva Pharmaceutical Industries Ltd
  • Mylan N.V.
  • Zimmer Biomet
  • Stryker
  • Merck & Co.,Inc
  • Horizon Therapeutics plc
  • Biotek.
  • Upsher-Smith Laboratories, LLC

リストは網羅的ではない

第13章 付録

目次
Product Code: PH7228

Overview

Osteonecrosis, also known as avascular necrosis or aseptic necrosis, is a medical condition that results in the death or necrosis of bone tissue due to a lack of blood flow. When blood flow to a certain bone is disturbed or limited, the bone cells deteriorate and eventually succumb.

The global osteonecrosis treatment market encompasses of various treatment such as Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), cholesterol-lowering drugs, blood thinners. The market is driven by the factors such as increasing prevalence of osteonecrosis, excess use of steroids, traumatics injuries, increasing geriatric population and technological advancements.

Market Dynamics: Drivers and Restraints

The increasing number of alcohol consumption

The rising consumption of alcohol is one of the primary drivers of the osteonecrosis treatment market. Excessive alcohol use is an important risk factor for osteonecrosis because it inhibits blood circulation, reducing blood flow to bones, particularly weight-bearing joints like the hip and knee.

For instance, according to the National Library of Medicine 2023 article, alcohol intake is a major risk factor for osteonecrosis, affecting 20-45% of people with the disorder. Furthermore, the prevalence of aseptic necrosis in habitual drinkers was reported to be as high as 5.3%.

Furthermore, the rising prevalence of sickle cell anemia, a genetic blood disease characterized by malformed, sickle-shaped red blood cells that block small blood cells, restricting blood supply to organs including bones, may result in osteonecrosis. This decreased blood supply causes ischemia, which causes bone tissue cells to die due to a lack of oxygen and nutrients. For instance, according to a National Library of Medicine 2022 article, osteonecrosis of the femoral head has been described to be 22% in patients with sickle cell disease and up to 50%.

Moreover, other factors such as increasing number of steriod use, increasing prevalence of systemic lupus erythematosus, gaucher disease and kidney transplantation are expected to drive the market over the forecast period.

Market Dynamics: Restraint

The high cost assoicated with the available treatments, risk factors associated with treatment drugs. Moreover, the limited awareness of disease symptoms, and a scarcity of treatment options for advanced stages, often necessitating joint replacement surgery. Thus, restraining the osteonecrosis treatment market over the foreseenable period.

Segment Analysis

The global osteonecrosis treatment market is segmented based on type, treatment, sales channel and region.

The surgery segment accounted for approximately 51.2% of the osteonecrosis treatment market share

The treatment segment in which surgery total joint replacement segment is expected to dominate the market. The total joint replacement is the treatment of choice in late-stage osteonecrosis when the joint is destroyed. In this surgery, the diseased joint is replaced with artificial parts. It may be recommended for people who are not good candidates for other treatments, such as patients who do not do well with repeated attempts to preserve the joint.

For instance, in February 2021, the U.S. Food and Drug Administration (FDA) approved the Patient Specific Talus Spacer 3D-printed talus implant for humanitarian use. The Patient Specific Talus Spacer is the first-of-its-kind implant to replace the talus-the bone in the ankle joint that connects the leg and foot-for the treatment of AVN of the ankle joint. Thus, owing to the above factors the segment is expected to dominate over the forecast period.

Geographical Penetration

North America accounted for approximately 37.4% of the market share in 2022

The North America region particulary the U.S. is expected to dominate the market owing to the factors such as increasing prevalence of osteonecrosis, increasing number of clinical trial, and presence of key market players in this region

For instance, according to National Organization for Rare Disorders 2021 article, in U.S. osteonecrosis is particularly seen in people aging around 30 to 50 years of age that accounts about 10,000 to 20,000 people suffering from osteonecrosis in this country.

Furthermore, in May 2022, Regrow Biosciences has received approval from the USFDA to begin a phase II study of its lead product 'OSSGROW,' an orphan medicine that aids in the effective treatment of Osteonecrosis, in the US market. Regrow Biosciences has received an Orphan Drug Designation (ODD) from the USFDA and EMA for OSSGROW. Thus, owing to the above factors the region is expected to dominate over the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has had significant effects on the osteonecrosis treatment market, owing to the widespread usage of steroids in COVID-19 patient care. Steroid therapy during the early stages of COVID-19 resulted in a significant increase in the incidence of avascular necrosis (AVN) among patients. As a result, there was an increase in demand for osteonecrosis treatment alternatives, such as pharmacological treatments and surgical operations. This increased demand put further strain on healthcare infrastructure, with hospitals having to choose between COVID-19 and AVN patients. However, the situation offered chances for research and development, promoting the study of novel AVN therapy.

Regional differences in AVN cases emerged, as evidenced by India's Apollo Hospitals, which treated a large number of AVN patients. As the healthcare sector adjusts to the post-pandemic landscape, vigilance, responsiveness to changing patient needs, and ongoing research in osteonecrosis treatment remain critical, while public health guidelines should be continually refined to reduce future treatment-related complications in healthcare crises.

Competitive Landscape

The major global players in the osteonecrosis treatment market include: Novartis AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Mylan N.V., Zimmer Biomet, Stryker, Merck & Co.,Inc, Horizon Therapeutics plc, Biotek., Upsher-Smith Laboratories, LLC, and among others.

Key Developments

  • On February 17, 2021, The Patient Specific Talus Spacer 3D-printed talus implant has been approved for humanitarian use by the US Food and Drug Administration. The Patient Specific Talus Spacer is a first-of-its-kind implant that replaces the talus-the bone in the ankle joint that connects the leg and the foot-for the treatment of avascular necrosis (AVN) of the ankle joint, a serious and progressive condition that causes bone tissue death due to a lack of blood supply to the area.

Why Purchase the Report?

  • To visualize the global osteonecrosis treatment market segmentation based on type, treatment, sales channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of osteonecrosis treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping is available in excel consisting of key products of all the major players.

The global osteonecrosis treatment market report would provide approximately 61 tables, 54 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Treatment
  • 3.3. Snippet by Sales Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The increasing number of alcohol consumption
    • 4.1.2. Restraints
      • 4.1.2.1. The high cost associated with the treatment
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Traumatic*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Non-traumatic

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.1.2. Market Attractiveness Index, By Treatment Type
  • 8.2. Medication*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
      • 8.2.2.1. Antiresorptive Drugs
      • 8.2.2.2. Nonsteroidal Anti-Inflammatory Drugs
      • 8.2.2.3. Cholesterol-Lowering Drugs
      • 8.2.2.4. Blood Thinners
      • 8.2.2.5. Others
  • 8.3. Surgery
      • 8.3.1.1. Core decompression surgery
      • 8.3.1.2. Osteotomy
      • 8.3.1.3. Bone graft
      • 8.3.1.4. Total joint replacement
      • 8.3.1.5. Others

9. By Sales Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 9.1.2. Market Attractiveness Index, By Sales Channel
  • 9.2. End User*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
      • 9.2.2.1. Hospitals
      • 9.2.2.2. Orthopedic Clinics
      • 9.2.2.3. Ambulatory Surgical Centers
      • 9.2.2.4. Specialty Clinics
      • 9.2.2.5. Others
  • 9.3. Distribution Channel
      • 9.3.1.1. Hospital Pharmacies
      • 9.3.1.2. Retail Pharmacies
      • 9.3.1.3. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Spain
      • 10.3.6.5. Italy
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Novartis AG*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Pfizer Inc
  • 12.3. Teva Pharmaceutical Industries Ltd
  • 12.4. Mylan N.V.
  • 12.5. Zimmer Biomet
  • 12.6. Stryker
  • 12.7. Merck & Co.,Inc
  • 12.8. Horizon Therapeutics plc
  • 12.9. Biotek.
  • 12.10. Upsher-Smith Laboratories, LLC

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us